Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis.

Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):169-76. doi: 10.1161/ATVBAHA.108.179275. Epub 2009 Oct 8. Review. Erratum in: Arterioscler Thromb Vasc Biol.2010 Sep;30(9):e176.


Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression.

Chen W, Cormode DP, Vengrenyuk Y, Herranz B, Feig JE, Klink A, Mulder WJ, Fisher EA, Fayad ZA.

JACC Cardiovasc Imaging. 2013 Mar;6(3):373-84. doi: 10.1016/j.jcmg.2012.06.016. Epub 2013 Feb 20.


Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles.

Shen ZT, Zheng S, Gounis MJ, Sigalov AB.

PLoS One. 2015 Nov 16;10(11):e0143453. doi: 10.1371/journal.pone.0143453. eCollection 2015.


Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging.

Mulder WJ, Strijkers GJ, van Tilborg GA, Cormode DP, Fayad ZA, Nicolay K.

Acc Chem Res. 2009 Jul 21;42(7):904-14. doi: 10.1021/ar800223c.


Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis.

Marrache S, Dhar S.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9445-50. doi: 10.1073/pnas.1301929110. Epub 2013 May 13.


Modified lipoproteins as contrast agents for imaging of atherosclerosis.

Frias JC, Lipinski MJ, Lipinski SE, Albelda MT.

Contrast Media Mol Imaging. 2007 Jan-Feb;2(1):16-23. Review.


Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis.

Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, Barazza A, Fisher EA, Dathe M, Fayad ZA.

Contrast Media Mol Imaging. 2008 Nov-Dec;3(6):233-42. doi: 10.1002/cmmi.257.


The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis.

Skajaa T, Cormode DP, Jarzyna PA, Delshad A, Blachford C, Barazza A, Fisher EA, Gordon RE, Fayad ZA, Mulder WJ.

Biomaterials. 2011 Jan;32(1):206-13. doi: 10.1016/j.biomaterials.2010.08.078.


Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages.

Sigalov AB.

Contrast Media Mol Imaging. 2014 Sep-Oct;9(5):372-82. doi: 10.1002/cmmi.1587. Epub 2014 Apr 14.


Intraperitoneal injection improves the uptake of nanoparticle-labeled high-density lipoprotein to atherosclerotic plaques compared with intravenous injection: a multimodal imaging study in ApoE knockout mice.

Jung C, Kaul MG, Bruns OT, Dučić T, Freund B, Heine M, Reimer R, Meents A, Salmen SC, Weller H, Nielsen P, Adam G, Heeren J, Ittrich H.

Circ Cardiovasc Imaging. 2014 Mar;7(2):303-11. doi: 10.1161/CIRCIMAGING.113.000607. Epub 2013 Dec 19.


Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles.

Cormode DP, Roessl E, Thran A, Skajaa T, Gordon RE, Schlomka JP, Fuster V, Fisher EA, Mulder WJ, Proksa R, Fayad ZA.

Radiology. 2010 Sep;256(3):774-82. doi: 10.1148/radiol.10092473. Epub 2010 Jul 28.


Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis.

Cormode DP, Chandrasekar R, Delshad A, Briley-Saebo KC, Calcagno C, Barazza A, Mulder WJ, Fisher EA, Fayad ZA.

Bioconjug Chem. 2009 May 20;20(5):937-43. doi: 10.1021/bc800520d.


Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI).

Smith BR, Heverhagen J, Knopp M, Schmalbrock P, Shapiro J, Shiomi M, Moldovan NI, Ferrari M, Lee SC.

Biomed Microdevices. 2007 Oct;9(5):719-27. Erratum in: Biomed Microdevices. 2008 Feb;10(1):129-30.


Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study.

Virani SS, Catellier DJ, Pompeii LA, Nambi V, Hoogeveen RC, Wasserman BA, Coresh J, Mosley TH, Otvos JD, Sharrett AR, Boerwinkle E, Ballantyne CM.

Atherosclerosis. 2011 Dec;219(2):596-602. doi: 10.1016/j.atherosclerosis.2011.08.001. Epub 2011 Aug 7.


Histological validation of iron-oxide and gadolinium based MRI contrast agents in experimental atherosclerosis: the do's and don't's.

den Adel B, Bovens SM, te Boekhorst B, Strijkers GJ, Poelmann RE, van der Weerd L, Pasterkamp G.

Atherosclerosis. 2012 Dec;225(2):274-80. doi: 10.1016/j.atherosclerosis.2012.07.028. Epub 2012 Jul 27. Review.


Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform.

Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, Zanzonico P, Fisher EA, Fayad ZA, Mulder WJ.

Nano Lett. 2008 Nov;8(11):3715-23. doi: 10.1021/nl801958b. Epub 2008 Oct 22.


Characterization and molecular detection of atherothrombosis by magnetic resonance--potential tools for individual risk assessment and diagnostics.

Ala-Korpela M, Sipola P, Kaski K.

Ann Med. 2006;38(5):322-36. Review. Erratum in: Ann Med. 2006;38(7):528.


Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions.

Briley-Saebo K, Yeang C, Witztum JL, Tsimikas S.

J Cardiovasc Transl Res. 2014 Nov;7(8):719-36. doi: 10.1007/s12265-014-9590-4. Epub 2014 Oct 9. Review.


Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.

Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang BY, Mehta JL, Beller GA, Glover DK, Meyer CH.

Circ Cardiovasc Imaging. 2010 Jul;3(4):464-72. doi: 10.1161/CIRCIMAGING.109.896654. Epub 2010 May 4.

Supplemental Content

Support Center